
|Videos|February 8, 2016
Will Biosimilars Reduce Specialty Drug Spending?
Author(s)Davy James, Managing Editor
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Advertisement
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
2
FAQ: Guidance for Pharmacists, SSRIs Under Scrutiny and Political Debate
3
Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Tirzepatide
4
FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC
5



































































































































